GlassScriptPhysician profile
Amelia M Case
NPI 1942507603
$5,982.97
in general payments reported to CMS, 2019-2025
38 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $733 · 2022: $948 · 2023: $1,309 · 2024: $1,504 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,301.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.71 | 2021-2025 | |
| Pfizer INC. | $613.08 | 2021-2025 | |
| Glaxosmithkline, LLC. | $566.33 | 2021-2025 | Trelegy Ellipta, Shingrix, Pediarix |
| Otsuka America Pharmaceutical, INC. | $452.19 | 2022-2025 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $407.65 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $288.55 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.29 | 2021-2023 | Jardiance, Ofev, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $225.71 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $211.80 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Abbott Laboratories | $190.01 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Medtronic, INC. | $157.50 | 2024 | Endurant Iis |
| Boston Scientific Corporation | $145.94 | 2024 | Watchman Flx |
| Antares Pharma, INC. | $128.50 | 2025 | Xyosted |
| Lundbeck LLC | $121.70 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $112.43 | 2021-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.